Preview Mode Links will not work in preview mode

Feb 26, 2020

Acute Leukemias Update, Issue 1, 2020 — Part 2: Our interview with Dr Wang highlights the following topics as well as cases from her practice:

  • Case: A woman in her early 60s with previously treated metastatic triple-negative breast cancer is diagnosed with AML with a FLT3-ITD mutation (00:00)
  • Molecular profiling in the diagnosis and treatment of AML (01:54)
  • Activity and tolerability of midostaurin in combination with standard 7 + 3 chemotherapy for newly diagnosed AML with a FLT3 mutation (05:14)
  • CPX-351 for secondary AML (07:16)
  • Incidence and characterization of FLT3 mutations in AML; efficacy of midostaurin and gilteritinib (10:45)
  • Clinical experience with and tolerability of gilteritinib (16:12)
  • Activity of midostaurin in newly diagnosed AML with a FLT3 mutation (20:54)
  • Ongoing Phase III trials of crenolanib, gilteritinib and quizartinib as first-line therapy for AML with a FLT3 mutation (24:17)
  • Significance of allelic ratio in AML with a FLT3-ITD mutation (26:50)
  • Therapeutic options for patients with relapsed/refractory AML and metastatic triple-negative breast cancer (31:01)
  • Activity and safety of immune checkpoint inhibitors in patients with AML (32:58)
  • Biologic rationale for and activity of venetoclax in combination with a hypomethylating agent for patients with AML (35:06)
  • Case: A man in his early 40s with relapsed/refractory AML with an IDH2 mutation receives enasidenib (36:32)
  • Similarities and differences between enasidenib and ivosidenib; recognition and management of treatment-associated differentiation syndrome (39:22)
  • Integration of the FDA-approved IDH inhibitors enasidenib and ivosidenib into clinical practice (44:15)
  • Approach to therapy for older patients with AML with FLT3 or IDH1/2 mutations (46:56)
  • Integration of venetoclax in combination with a hypomethylating agent into community practice (51:23)
  • Use of gemtuzumab ozogamicin for patients with low- to intermediate-risk AML with no adverse cytogenetics (55:33)
  • Activity and unique side-effect profile of the hedgehog inhibitor glasdegib for AML (58:17)
  • Results of the Phase III QUAZAR AML-001 trial: Overall survival benefit with CC-486 as maintenance therapy for newly diagnosed AML in first remission (1:00:34)
  • Mechanism of action and activity of the first-in-class small molecule APR-246 in combination with azacitidine for patients with AML or myelodysplastic syndromes with TP53 mutations (1:04:19)
  • Mechanisms of action and activity of blinatumomab and the antibody-drug conjugate inotuzumab ozogamicin in patients with relapsed/refractory ALL (1:06:44)
  • Tolerability and safety of blinatumomab and inotuzumab ozogamicin (1:09:51)

CME information and select publications